CA2901993C - Use of pyrazolopyrimidine derivatives for the treatment of pi3k.delta. related disorders - Google Patents
Use of pyrazolopyrimidine derivatives for the treatment of pi3k.delta. related disorders Download PDFInfo
- Publication number
- CA2901993C CA2901993C CA2901993A CA2901993A CA2901993C CA 2901993 C CA2901993 C CA 2901993C CA 2901993 A CA2901993 A CA 2901993A CA 2901993 A CA2901993 A CA 2901993A CA 2901993 C CA2901993 C CA 2901993C
- Authority
- CA
- Canada
- Prior art keywords
- chloro
- compound
- pyrazolo
- mmol
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771480P | 2013-03-01 | 2013-03-01 | |
| US61/771,480 | 2013-03-01 | ||
| PCT/US2014/019372 WO2014134426A1 (en) | 2013-03-01 | 2014-02-28 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2901993A1 CA2901993A1 (en) | 2014-09-04 |
| CA2901993C true CA2901993C (en) | 2023-03-07 |
Family
ID=50288319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2901993A Active CA2901993C (en) | 2013-03-01 | 2014-02-28 | Use of pyrazolopyrimidine derivatives for the treatment of pi3k.delta. related disorders |
Country Status (32)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2448938B9 (en) | 2009-06-29 | 2015-06-10 | Incyte Corporation | Pyrimidinones as pi3k inhibitors |
| KR102030609B1 (ko) | 2011-09-02 | 2019-10-11 | 인사이트 홀딩스 코포레이션 | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| CA2897200C (en) | 2013-01-14 | 2021-07-06 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| PE20191245A1 (es) | 2013-01-15 | 2019-09-18 | Incyte Holdings Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
| TWI736135B (zh) * | 2013-03-01 | 2021-08-11 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| CN105658653A (zh) | 2013-08-23 | 2016-06-08 | 因赛特公司 | 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物 |
| KR20240153401A (ko) | 2014-04-08 | 2024-10-22 | 인사이트 홀딩스 코포레이션 | Ｊａｋ 및 ｐｉ3ｋ 억제제 조합에 의한 ｂ-세포 악성종양의 치료 |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
| DK3831833T3 (da) * | 2015-02-27 | 2022-11-14 | Incyte Holdings Corp | Fremgangsmåder til fremstillingen af en pi3k-inhibitor |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| EP4086259A1 (en) | 2015-11-06 | 2022-11-09 | Incyte Corporation | Heterocyclic compounds as pi3k-gamma inhibitors |
| WO2017120194A1 (en) | 2016-01-05 | 2017-07-13 | Incyte Corporation | Pyridine and pyridimine compounds as pi3k-gamma inhibitors |
| KR102514814B1 (ko) | 2016-03-31 | 2023-03-27 | 온크터널 테라퓨틱스, 인코포레이티드. | 인돌린 유사체 및 이의 용도 |
| WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
| EP3679042B1 (en) * | 2017-09-08 | 2023-03-01 | BeiGene, Ltd. | IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS |
| IL295978B2 (en) | 2017-10-18 | 2024-01-01 | Incyte Corp | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| EP3737684B1 (en) * | 2018-01-10 | 2022-11-16 | Idorsia Pharmaceuticals Ltd | 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases |
| TWI903299B (zh) | 2018-03-08 | 2025-11-01 | 美商英塞特公司 | 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物 |
| CN119258070A (zh) | 2018-06-01 | 2025-01-07 | 因赛特公司 | 治疗pi3k相关病症的给药方案 |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| TWI727392B (zh) * | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | 噻二唑irak4抑制劑 |
| CN110833552A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗狼疮肾炎的用途 |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| JP2023551519A (ja) | 2020-11-30 | 2023-12-08 | インサイト・コーポレイション | 抗ｃｄ１９抗体とパルサクリシブの組み合わせ療法 |
| WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| CN112808550B (zh) * | 2020-12-28 | 2021-10-01 | 青岛理工大学 | 用于海洋工程的劣化免疫仿生防护界面及制备方法 |
| WO2023114369A2 (en) | 2021-12-16 | 2023-06-22 | Incyte Corporation | Topical formulations of pi3k-delta inhibitors |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| WO2000009495A1 (en) | 1998-08-11 | 2000-02-24 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| DE60105023T2 (de) | 2000-06-28 | 2005-08-18 | Smithkline Beecham P.L.C., Brentford | Nassvermahlungsverfahren |
| MXPA04002243A (es) | 2001-09-19 | 2004-06-29 | Aventis Pharma Sa | Compuestos quimicos. |
| CN101703509A (zh) | 2001-10-30 | 2010-05-12 | 诺瓦提斯公司 | 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物 |
| AR037647A1 (es) | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| CN1960988B (zh) | 2004-06-10 | 2012-01-25 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| BRPI0517887A (pt) | 2004-11-24 | 2008-10-21 | Novartis Ag | combinações de inibidores de jaks |
| AR060316A1 (es) | 2006-01-17 | 2008-06-11 | Vertex Pharma | Azaindoles de utilidad como inhibidores de janus quinasas |
| TW200916447A (en) | 2007-08-29 | 2009-04-16 | Methylgene Inc | Sirtuin inhibitors |
| US20110105500A1 (en) | 2008-06-27 | 2011-05-05 | S*Bio Pte Ltd. | Pyrazine substituted purines |
| AR073651A1 (es) * | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| WO2010036380A1 (en) * | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| MX2011010631A (es) | 2009-04-09 | 2012-01-20 | Oncothyreon Inc | Metodos y composiciones de inhibidores de quinasa pi-3 para tratar fibrosis. |
| EP2448938B9 (en) | 2009-06-29 | 2015-06-10 | Incyte Corporation | Pyrimidinones as pi3k inhibitors |
| US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| AR077974A1 (es) | 2009-08-28 | 2011-10-05 | Takeda Pharmaceutical | Compuestos de hexahidrooxazinopterina para uso como inhibidores de mtor |
| AR079529A1 (es) | 2009-12-18 | 2012-02-01 | Incyte Corp | Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
| AU2012212323A1 (en) | 2011-02-01 | 2013-09-12 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| KR102030609B1 (ko) | 2011-09-02 | 2019-10-11 | 인사이트 홀딩스 코포레이션 | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| TWI736135B (zh) * | 2013-03-01 | 2021-08-11 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| WO2015191677A1 (en) * | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| DK3831833T3 (da) * | 2015-02-27 | 2022-11-14 | Incyte Holdings Corp | Fremgangsmåder til fremstillingen af en pi3k-inhibitor |
| CN119258070A (zh) | 2018-06-01 | 2025-01-07 | 因赛特公司 | 治疗pi3k相关病症的给药方案 |
| WO2020102150A1 (en) * | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
-
2014
- 2014-02-27 TW TW109104878A patent/TWI736135B/zh active
- 2014-02-27 TW TW112117019A patent/TWI841376B/zh active
- 2014-02-27 TW TW110124946A patent/TW202214254A/zh unknown
- 2014-02-27 TW TW108100664A patent/TWI687220B/zh active
- 2014-02-27 TW TW103106906A patent/TWI657090B/zh active
- 2014-02-28 CN CN201480021187.1A patent/CN105120871B/zh active Active
- 2014-02-28 ES ES14710739T patent/ES2774436T3/es active Active
- 2014-02-28 SG SG10201912275YA patent/SG10201912275YA/en unknown
- 2014-02-28 EP EP19208523.1A patent/EP3632442B1/en active Active
- 2014-02-28 EP EP14710739.5A patent/EP2961410B1/en active Active
- 2014-02-28 HU HUE14710739A patent/HUE047719T2/hu unknown
- 2014-02-28 JP JP2015560346A patent/JP6545106B2/ja active Active
- 2014-02-28 IL IL301180A patent/IL301180A/en unknown
- 2014-02-28 PH PH1/2021/552233A patent/PH12021552233A1/en unknown
- 2014-02-28 SG SG11201506654UA patent/SG11201506654UA/en unknown
- 2014-02-28 SI SI201431449T patent/SI2961410T1/sl unknown
- 2014-02-28 CN CN201810796220.8A patent/CN109010343A/zh active Pending
- 2014-02-28 AR ARP140100679A patent/AR094964A1/es unknown
- 2014-02-28 DK DK14710739.5T patent/DK2961410T3/da active
- 2014-02-28 IL IL311666A patent/IL311666A/en unknown
- 2014-02-28 KR KR1020237033761A patent/KR102717616B1/ko active Active
- 2014-02-28 HR HRP20200263TT patent/HRP20200263T1/hr unknown
- 2014-02-28 PT PT147107395T patent/PT2961410T/pt unknown
- 2014-02-28 AU AU2014223257A patent/AU2014223257B2/en active Active
- 2014-02-28 EA EA201591612A patent/EA201591612A1/ru unknown
- 2014-02-28 MX MX2015011273A patent/MX367713B/es active IP Right Grant
- 2014-02-28 RS RS20200176A patent/RS59958B1/sr unknown
- 2014-02-28 ES ES19208523T patent/ES2945212T3/es active Active
- 2014-02-28 SG SG10201707130UA patent/SG10201707130UA/en unknown
- 2014-02-28 SM SM20200043T patent/SMT202000043T1/it unknown
- 2014-02-28 EA EA202192151A patent/EA202192151A1/ru unknown
- 2014-02-28 LT LTEP14710739.5T patent/LT2961410T/lt unknown
- 2014-02-28 KR KR1020157027010A patent/KR102298150B1/ko active Active
- 2014-02-28 PE PE2015001833A patent/PE20151996A1/es not_active Application Discontinuation
- 2014-02-28 CA CA2901993A patent/CA2901993C/en active Active
- 2014-02-28 US US14/193,481 patent/US9932341B2/en active Active
- 2014-02-28 UA UAA201509435A patent/UA119641C2/uk unknown
- 2014-02-28 BR BR112015020941A patent/BR112015020941A2/pt not_active Application Discontinuation
- 2014-02-28 EP EP23161858.8A patent/EP4233869A3/en active Pending
- 2014-02-28 WO PCT/US2014/019372 patent/WO2014134426A1/en not_active Ceased
- 2014-02-28 MY MYPI2015002108A patent/MY177875A/en unknown
- 2014-02-28 KR KR1020247033698A patent/KR20240152422A/ko active Pending
- 2014-02-28 KR KR1020217027697A patent/KR102454308B1/ko active Active
- 2014-02-28 KR KR1020227035039A patent/KR102586858B1/ko active Active
- 2014-02-28 PL PL14710739T patent/PL2961410T3/pl unknown
-
2015
- 2015-08-24 IL IL240784A patent/IL240784B/en not_active IP Right Cessation
- 2015-08-28 MX MX2019010422A patent/MX2019010422A/es unknown
- 2015-08-31 CL CL2015002442A patent/CL2015002442A1/es unknown
- 2015-09-01 PH PH12015501920A patent/PH12015501920A1/en unknown
- 2015-09-10 CR CR20150472A patent/CR20150472A/es unknown
-
2018
- 2018-03-02 US US15/910,708 patent/US20190040067A1/en not_active Abandoned
- 2018-11-14 AU AU2018264053A patent/AU2018264053B2/en active Active
-
2019
- 2019-04-25 JP JP2019084393A patent/JP6776399B2/ja active Active
- 2019-06-11 PH PH12019501321A patent/PH12019501321B1/en unknown
- 2019-07-04 IL IL267853A patent/IL267853B/en active IP Right Grant
-
2020
- 2020-02-26 CY CY20201100177T patent/CY1122712T1/el unknown
- 2020-05-19 IL IL274771A patent/IL274771A/en unknown
- 2020-07-31 AU AU2020210278A patent/AU2020210278B2/en active Active
- 2020-10-07 JP JP2020169551A patent/JP7189185B2/ja active Active
-
2021
- 2021-06-13 IL IL283943A patent/IL283943B2/en unknown
- 2021-06-30 US US17/364,695 patent/US20210332059A1/en not_active Abandoned
- 2021-06-30 US US17/364,551 patent/US12152033B2/en active Active
- 2021-06-30 US US17/364,585 patent/US20220119393A1/en not_active Abandoned
-
2022
- 2022-08-16 AU AU2022218495A patent/AU2022218495B2/en active Active
- 2022-12-01 JP JP2022192954A patent/JP7556010B2/ja active Active
-
2024
- 2024-09-11 JP JP2024157116A patent/JP2025003975A/ja active Pending
- 2024-10-24 US US18/926,010 patent/US20250289823A1/en active Pending
- 2024-12-23 AU AU2024287194A patent/AU2024287194A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022218495B2 (en) | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS | |
| AU2017206260B2 (en) | Heterocyclylamines as pi3k inhibitors | |
| HK40098131A (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders | |
| HK40027828A (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders | |
| HK40011502B (en) | Heterocyclylamines as pi3k inhibitors | |
| HK40011502A (en) | Heterocyclylamines as pi3k inhibitors | |
| HK1241863B (en) | Heterocyclylamines as pi3k inhibitors | |
| HK1221398B (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders | |
| NZ765458B2 (en) | Heterocyclylamines as pi3k inhibitors | |
| NZ735378B2 (en) | Heterocyclylamines as pi3k inhibitors | |
| NZ751428B2 (en) | Heterocyclylamines as pi3k inhibitors | |
| NZ717505B2 (en) | Heterocyclylamines as pi3k inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190228 |
|
| EEER | Examination request |
Effective date: 20190228 |
|
| EEER | Examination request |
Effective date: 20190228 |
|
| EEER | Examination request |
Effective date: 20190228 |
|
| EEER | Examination request |
Effective date: 20190228 |
|
| EEER | Examination request |
Effective date: 20190228 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250226 |